Amgen Launches Preemptive Strike in Patent Battle
Amgen’s complaint against rival drug company Ariad Pharmaceuticals Inc., which was filed Thursday, implies that future patent infringement claims against Amgen’s drugs Enbrel and Kineret are a virtual certainty. Those claims would stem from Ariad’s patent—U.S. Patent no. 6,410,516—which covers the regulation of NF-(kappa)B cell-signaling activity as a treatment for disease.
To view the full article, register now.